Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

SAN FRANCISCO, August 30, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th, the CL King 16th Annual Best Ideas Conference and the Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference, both […]

Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

SAN FRANCISCO, August 21, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4th in New York at the New York Marriott East Side. Denise Bevers, Co-Founder and Chief Operating Officer, will be […]

Kindred Biosciences Announces Second Quarter 2018 Financial Results

San Francisco, CA (August 9, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2018 and provided updates on its programs. “We are encouraged so far by the response from veterinarians, distributors, and cat […]

Kindred Biosciences to Announce Second Quarter 2018 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, August 9, 2018 San Francisco, CA (July 16, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter […]

Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

SAN FRANCISCO, July 9, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats is commercially available to veterinarians in the United States. Mirataz is the first and only transdermal medication for the […]